Life Biosciences announced interim data from the first human trial of ER-100, its epigenetic-restoration therapy for optic neuropathies. A single intravitreal administration of Dose Level 1 (2x10^11 vg) along with daily oral doxycycline, used to induce expression of the OSK transcription factors OCT4, SOX2 and KLF4, was well tolerated through day 56 in three participants with open-angle glaucoma. There were no dose-limiting toxicities, no adverse events of special interest and no serious adverse events, and the data safety monitoring board recommended escalation to Dose Level 2.
The trial is designed around safety and tolerability, but the company also reported preliminary signals of improvement in visual field testing in two of the three participants. ER-100 is the first clinical candidate from Life Biosciences’ epigenetic-restoration platform, which aims to reset the epigenetic code to more youthful patterns of gene expression; co-founder David Sinclair has argued that aging is driven largely by loss of epigenetic information rather than irreversible damage. The Phase 1 trial also targets non-arteritic anterior ischemic optic neuropathy.
The data are early, with three patients and a 56-day window, but clean safety is the gating item for a modality that has lived entirely in animal models until now. Glaucoma is a disease where vision loss is generally considered irreversible, so any durable functional signal at higher doses would draw close attention. The program sits at the intersection of gene therapy delivery and aging biology, a combination that has attracted heavy private capital but has yet to produce human efficacy data.